Therapeutic Specialist - Pain
About the job
- A bachelor's degree is required.
- Two to four years of pharmaceutical or life sciences industry experience are required.
- Strong account-based selling skills and demonstrated success in prior sales roles are required.
- Proficiency with Microsoft Office, including Excel, Outlook, PowerPoint, and Word, is required.
- A valid driver's license and insurability are required.
- Seek and foster strong business relationships with health care partners and customers.
- Develop a plan to meet with target customers in the assigned territory and serve as a clinical resource for customers.
- Organize and execute sales presentations.
- Maintain knowledge of competitors' products, service offerings, and activity.
- Effectively deliver product fair-balance information to appropriate customers.
- Plan and execute an effective call plan.
- Increase market share for Collegium's product portfolio.
- Uphold and consistently demonstrate Collegium's Core Values.
- Deliver quality work on time and with minimal errors.
- Explain information related to one's own output.
- Work on problems and ideas of some complexity within defined guidelines.
- Continue to increase understanding of the job.
- Manage one's own work while beginning to operate with some independence.
- Proven success in an entrepreneurial environment is preferred.
Collegium Pharmaceutical is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. We have a leading portfolio of responsible pain management and neuropsychiatry medications.
POSITION OVERVIEW
The Therapeutic Specialist, Pain, will be responsible for implementing Collegium’s sales/marketing plan to assure maximum market penetration. This role will develop relationships with target Health Care Professionals (HCPs) office personnel to carry out Collegium’s mission of becoming the leader in responsible pain management.
RESPONSIBILITIES
- Seek and foster strong business relationships with health care partners and customers
- Develop plan to meet with target customers in assigned territory and serve as a clinical resource for customers
- Organize and execute sales presentations
- Knowledgeable of the competition's products, service offerings, and activity
- Deliver product fair balance information to appropriate customers effectively
- Plan and execute effective call plan
- Increase Collegium product portfolio market share
- Uphold and consistently demonstrate Collegium’s Core Values
- Be accountable for delivery of quality work on time and with minimal errors
- Explain information related to own output
- Work on problems and ideas of some complexity with defined guidelines
- Continue to increase depth of understanding of job
- Manage self but beginning to operate with some independence
REQUIRED LEADERSHIP BEHAVIORS
At Collegium, how we achieve results is just as important as what we achieve. Our Leadership Behaviors define how we work, collaborate, and succeed as we continue to evolve as an organization.
We group these behaviors into three pillars:
- HEAD
- Think Entrepreneurially
- Take Decisive Action
- Drive Results
- HEART
- Communicate Effectively
- Enable High Performance
- Collaborate with Purpose
- GUTS
- Take Smart Risks
- Be Tenacious About Change
- Compete to Win
Successful candidates will demonstrate these behaviors through their ability to challenge the status quo, build strong relationships, drive results, embrace change, and contribute to a high-performance culture.
QUALIFICATIONS
- Bachelor’s degree required
- 2-4 years of Pharmaceutical/Life Science industry experience required
- Strong account based selling skills with demonstrated success in prior sales roles
- Proven success in an entrepreneurial environment preferred
- Proficiency with Microsoft Office (Excel, Outlook, PowerPoint, Word) required
- Have a valid driver’s license and be insurable
Collegium is an equal opportunity employer. It is the policy of Collegium, in all of its relations with its employees and applicants for employment, to base all employment-related decisions upon valid job-related factors, without regard to age, national origin, citizenship status, ancestry, race, color, religion, creed, sex or gender (including pregnancy, childbirth and related medical conditions), gender identity or expression (including transgender status), sexual orientation, military or veteran status, physical or mental disability, genetic information, or any other status protected by applicable federal, state, or local law. This policy applies to hiring, training, promotion, compensation, disciplinary measures, access to facilities and programs, and all other personnel actions and conditions of employment. By this policy, Collegium seeks to ensure that all employees have the opportunity to make their maximum contribution to Collegium and to their own career goals. This policy provides for an equal employment opportunity program that will simultaneously serve the requirements of society, the law, sound business practices and individual dignity.
If you have questions or concerns about equal employment opportunities in the workplace, you are encouraged to bring these issues to the attention of the Head of Human Resources. We will not allow any form of retaliation against employees who raise issues of equal employment opportunity. To ensure our workplace is free of artificial barriers, violation of this policy may result in disciplinary action, up to and including termination.
Pay Range 115000 - 134500 USD
About the company
Preparing summary...
Company Size
201-500
Company Stage
IPO
Headquarters
Cumberland, Maryland
Founded
2002
Get referred to Collegium Pharmaceutical
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $199.9 million, up 6%, beating EPS at $1.92.
- JORNAY PM revenue hit $46.1 million, up 41%, with 30,000 prescribers.
- AZSTARYS added $12.9 million in May-June and management raised 2026 guidance.
What critics are saying
- Nucynta authorized generics cut pricing; Q2 pain revenue fell 9% and guidance dropped.
- August 2026 guidance cut reduced EBITDA midpoint to $457.5 million, signaling margin pressure.
- $650 million AZSTARYS acquisition plus debt leaves leverage exposed if ADHD growth slows.
What makes Collegium Pharmaceutical unique
- AZSTARYS and JORNAY PM create a two-product ADHD franchise with 2037 patent protection.
- Xtampza ER, BELBUCA, and Nucynta generate cash from diversified CNS and pain brands.
- Collegium's proprietary abuse-deterrent and extended-release technologies support premium positioning versus generics.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Hybrid Work Options
Growth & Insights and Company News
6 month growth
9%1 year growth
7%2 year growth
13%Collegium Pharmaceutical (NASDAQ:COLL) now covered by Oppenheimer. September 23, 2026 Key points. * Oppenheimer initiated coverage of Collegium Pharmaceutical with an "outperform" rating and a $50 price target, implying approximately 119.5% upside from the stock's $22.78 price. * Analyst sentiment is mixed but leans positive: six analysts rate the stock a Buy, two a Hold, and one a Sell, producing a "Moderate Buy" consensus and an average price target of $48.71. * Collegium exceeded quarterly expectations, reporting $1.92 in EPS versus the $1.72 estimate and $199.88 million in revenue; revenue increased 6.3% year over year. * MarketBeat previews the top five stocks to own by October 1st. Analysts at Oppenheimer assumed coverage on shares of Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) in a report released on Wednesday, Marketbeat.com reports. The brokerage set an "outperform" rating and a $50.00 price target on the specialty pharmaceutical company's stock. Oppenheimer's target price points to a potential upside of 119.49% from the stock's current price. Several other research firms have also commented on COLL. Needham & Company LLC cut their price target on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Piper Sandler reissued a "neutral" rating and issued a $43.00 price objective (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 7th. Weiss Ratings downgraded shares of Collegium Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, September 4th. Finally, Truist Financial started coverage on shares of Collegium Pharmaceutical in a research note on Wednesday, September 9th. They issued a "buy" rating and a $49.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical has an average rating of "Moderate Buy" and an average price target of $48.71. Collegium Pharmaceutical price performance. COLL stock opened at $22.78 on Wednesday. The stock has a 50-day moving average price of $28.68 and a two-hundred day moving average price of $32.45. Collegium Pharmaceutical has a 12-month low of $21.65 and a 12-month high of $50.79. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. The company has a market cap of $741.72 million, a PE ratio of 18.37 and a beta of 0.72. Discover more AI Stocks Analysis Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping analysts' consensus estimates of $1.72 by $0.20. The company had revenue of $199.88 million for the quarter, compared to the consensus estimate of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The company's quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the business posted $1.68 EPS. As a group, research analysts predict that Collegium Pharmaceutical will post 6.19 EPS for the current year. Hedge funds weigh in on Collegium Pharmaceutical. Hedge funds and other institutional investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd increased its stake in shares of Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company's stock worth $29,000 after buying an additional 427 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in Collegium Pharmaceutical by 42.2% in the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company's stock valued at $47,000 after acquiring an additional 418 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in Collegium Pharmaceutical by 51.8% during the 4th quarter. Hantz Financial Services Inc. now owns 2,602 shares of the specialty pharmaceutical company's stock valued at $120,000 after acquiring an additional 888 shares during the last quarter. Assetmark Inc. boosted its stake in Collegium Pharmaceutical by 9.3% during the 1st quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company's stock valued at $130,000 after acquiring an additional 335 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in Collegium Pharmaceutical by 17.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 4,174 shares of the specialty pharmaceutical company's stock worth $193,000 after acquiring an additional 611 shares in the last quarter. Collegium Pharmaceutical company profile. Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company's portfolio includes treatments for pain and attention deficit hyperactivity disorder (ADHD), with an emphasis on products that address unmet patient and healthcare-provider needs. Collegium's pain portfolio includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties; Nucynta and Nucynta ER, which contain tapentadol and are used to treat certain types of acute and chronic pain; and Belbuca, a buprenorphine buccal film for the management of chronic pain. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Collegium Pharmaceutical, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Collegium Pharmaceutical wasn't on the list. While Collegium Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates. Continue following MarketBeat
Collegium Pharmaceutical reported strong second-quarter 2026 results, driven by significant growth in its ADHD business. The company's Jornay PM product generated $46.1 million in net revenue, up 41% year-over-year, with prescriptions growing 13.1%. The number of healthcare providers prescribing Jornay PM reached an all-time high of over 30,000 in the quarter, representing a 17.6% increase from the same period last year. Collegium completed the acquisition of Azstarys in May, adding a complementary ADHD treatment to its portfolio. The company now operates with six differentiated medicines across its CNS and pain treatment portfolio. Chief executive Vikram Karnani highlighted that the Azstarys acquisition reinforces the company's strategy, initiated in 2024, to diversify beyond pain management and strengthen its position in the growing ADHD market. The company maintains an established pain business alongside its expanding ADHD franchise.
Why is Collegium Pharmaceutical stock tumbling today? Published 08/06/2026, 09:15 AM (C) Reuters. Investing.com - Shares of Collegium Pharmaceutical fell 13.2% in pre-open trading after the specialty biopharmaceutical company reported second-quarter 2026 financial results before the market open and simultaneously trimmed its full-year revenue outlook. The company posted net revenues of $199.9 million for the quarter, a 6.3% increase from the same period a year earlier, but the figure fell short of the roughly $201.2-$201.4 million analysts had penciled in; more damaging was the updated full-year revenue guidance, whose midpoint came in approximately 3.4% below prior Street estimates. On the earnings side, Collegium delivered adjusted EPS of $1.92, comfortably ahead of the consensus around $1.72, and adjusted EBITDA of $113.8 million also beat expectations. However, the pain portfolio - which includes BELBUCA, Xtampza ER, and the Nucynta franchise - generated quarterly net revenues of $140.9 million, reflecting ongoing headwinds from generic competition that have weighed on the segment. JORNAY PM continued its rapid ascent, rising 41% year-over-year to $46.1 million, and the newly acquired AZSTARYS contributed $12.9 million for a partial quarter following the $650 million acquisition completed in May, but these positives could not offset the market's reaction to the guidance cut. From a broader market perspective, the NASDAQ composite was modestly in the red on the day, providing a slightly unfavorable backdrop for growth-oriented healthcare names, though the index-level decline was far smaller than COLL's pre-market drop. The S&P 500 was essentially unchanged, suggesting the sell-off was driven almost entirely by company-specific factors rather than any macro or sector-wide event. -6.02 (-16.84%) Real-time Data · 15:16:48 · USD Taken together, the combination of a top-line miss, a meaningful downward revision to the full-year revenue outlook, and lingering concerns about the durability of the pain portfolio proved too much for investors to absorb, pushing the stock toward its 52-week low of $30.13 - effectively erasing the gains accumulated since the AZSTARYS acquisition was announced. Is your COLL trade worth the risk? Before you click "buy," know exactly where to set your stop-loss. Our Vision AI literally "sees" your COLL chart and delivers a complete risk management plan - entry, stop-loss, and profit target - in under 60 seconds. Protect your downside. Validate every trade. Invest smarter.
Collegium Pharmaceutical reported Q2 2026 revenue of $199.9 million, missing analyst estimates of $201.2 million but representing 6.3% year-on-year growth. The company's stock fell following the announcement. The pharmaceutical firm's full-year revenue guidance of $840 million came in 3.4% below analyst expectations. However, Collegium beat earnings estimates with non-GAAP profit of $1.92 per share, 8.8% above consensus. The company completed its acquisition of AZSTARYS and reported 41% revenue growth in its ADHD portfolio. Operating margin declined to 1.9% from 18.7% in the same quarter last year. EBITDA guidance of $457.5 million at midpoint fell short of analyst estimates of $482.8 million. Over the past five years, Collegium has grown sales at 19.9% annually, though recent two-year growth has moderated to 18.4%.
Collegium Pharmaceutical reported second quarter 2026 net revenues of $199.9 million, up 6% year-over-year. The company completed its acquisition of AZSTARYS in May, strengthening its ADHD portfolio. JORNAY PM generated $46.1 million in quarterly revenue, up 41% year-over-year, whilst AZSTARYS contributed $12.9 million from May 12 onwards. The pain portfolio produced $140.9 million in revenues, down 9% year-over-year. The company updated its full-year 2026 guidance, lowering product revenue expectations to $825-855 million from $865-895 million, primarily due to lower pricing on Nucynta generic versions. AZSTARYS revenue guidance increased to $65-75 million from $60-70 million. Collegium generated $71.3 million in operating cash flow during the quarter and ended with $129.5 million in cash and marketable securities.